Background: Interferons (IFNs) are potential antitumor agents, as they exhibit antiproliferative and differentiating properties, in addition to functioning in the defense against microbial infections. IFN exposure induces the regulation of expression levels of cellular proteins that mediate the pleiotropic effects of interferons. These effects may be mediated by soluble factors or by cell-cell interactions involving specific membrane proteins. The IFITM family of proteins are transmembrane proteins so named because their expression is IFN-inducible. IFITM proteins have been found upregulated in human colorectal carcinomas. Both mouse IFITM1 (also known as CD225) and IFITM3 demonstrate expression on the cell surfaces of primordial germ cells in a developmentally-regulated manner. They presumably modulate cell adhesion and influence cell differentiation. IFITM1 activity is required for primordial germ cell transit, and IFITM1 acts as a repulsive molecule by repelling non-IFITM1-expressing primordial germ cells from the mesoderm into the endoderm.
Description: Rabbit polyclonal to IFITM2
Immunogen: KLH conjugated synthetic peptide derived from IFITM2
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 15 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry/Immunofluorescence: 1/100;
·Immunoprecipitation: 1/50;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
